For a BRCA1+ patient with a history of stage IVB endometrioid ovarian carcinoma s/p upfront surgery and adjuvant chemotherapy who has now completed 3 years of maintenance niraparib and is NED, how would you counsel about discontinuing vs continuing PARPi therapy?

For this patient who has completed 3 years of niraparib and is NED, discontinuation is reasonable and supported by available evidence. The PFS benefit achieved will likely persist for years after stopping, while continuing exposes her to cumulative toxicity risks without a proven incremental benefit...